Bicara Therapeutics· @BicaraTx · X·· 4 days agoScore45
Body
We’ll be at #ESMO2026 this week!
HPV-negative head and neck squamous cell carcinoma (#HNSCC) is a distinct and clinically challenging subset of the disease, representing the vast majority of HNSCC
cases in the recurrent/metastatic setting.
Visit Booth #8012 to learn about our research and clinical development in HPV-negative HNSCC, or visit http://bicara.com.
83 views · 0 likes · 1 repost · 0 replies
Conference abstracts
NCT06295731NCT06295731matched by - **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
- **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
https://esmocongress.esmo.orgSource: Bicara Therapeutics · x.com